A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
© 2022. The Author(s)..
Increasing evidence has shown that Parkinson's disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K ("3K") αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood-brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 19(2022), 3 vom: 31. Apr., Seite 1018-1036 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nuber, Silke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alpha-Synuclein |
|---|
| Anmerkungen: |
Date Completed 21.07.2022 Date Revised 04.02.2024 published: Print-Electronic ErratumIn: Neurotherapeutics. 2022 Jul 6;:. - PMID 35792968 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13311-022-01199-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339746076 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339746076 | ||
| 003 | DE-627 | ||
| 005 | 20240204231918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13311-022-01199-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1280.xml |
| 035 | |a (DE-627)NLM339746076 | ||
| 035 | |a (NLM)35445353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nuber, Silke |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2022 | ||
| 500 | |a Date Revised 04.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Neurotherapeutics. 2022 Jul 6;:. - PMID 35792968 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Increasing evidence has shown that Parkinson's disease (PD) impairs midbrain dopaminergic, cortical and other neuronal subtypes in large part due to the build-up of lipid- and vesicle-rich α-synuclein (αSyn) cytotoxic inclusions. We previously identified stearoyl-CoA desaturase (SCD) as a potential therapeutic target for synucleinopathies. A brain-penetrant SCD inhibitor, YTX-7739, was developed and has entered Phase 1 clinical trials. Here, we report the efficacy of YTX-7739 in reversing pathological αSyn phenotypes in various in vitro and in vivo PD models. In cell-based assays, YTX-7739 decreased αSyn-mediated neuronal death, reversed the abnormal membrane interaction of amplified E46K ("3K") αSyn, and prevented pathological phenotypes in A53T and αSyn triplication patient-derived neurospheres, including dysregulated fatty acid profiles and pS129 αSyn accumulation. In 3K PD-like mice, YTX-7739 crossed the blood-brain barrier, decreased unsaturated fatty acids, and prevented progressive motor deficits. Both YTX-7739 treatment and decreasing SCD activity through deletion of one copy of the SCD1 gene (SKO) restored the physiological αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival in 3K αSyn mice. YTX-7739 efficiently reduced pS129 + and PK-resistant αSyn in both human wild-type αSyn and 3K mutant mice similar to the level of 3K-SKO. Together, these data provide further validation of SCD as a PD therapeutic target and YTX-7739 as a clinical candidate for treating human α-synucleinopathies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a alpha-Synuclein |2 NLM | |
| 650 | 7 | |a Stearoyl-CoA Desaturase |2 NLM | |
| 650 | 7 | |a EC 1.14.19.1 |2 NLM | |
| 700 | 1 | |a Chung, Chee Yeun |e verfasserin |4 aut | |
| 700 | 1 | |a Tardiff, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a Bechade, Pascal A |e verfasserin |4 aut | |
| 700 | 1 | |a McCaffery, Thomas D |e verfasserin |4 aut | |
| 700 | 1 | |a Shimanaka, Kazuma |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jeonghoon |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Belle |e verfasserin |4 aut | |
| 700 | 1 | |a Raja, Waseem |e verfasserin |4 aut | |
| 700 | 1 | |a Neves, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Burke, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Khurana, Vikram |e verfasserin |4 aut | |
| 700 | 1 | |a Dettmer, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Fanning, Saranna |e verfasserin |4 aut | |
| 700 | 1 | |a Rhodes, Kenneth J |e verfasserin |4 aut | |
| 700 | 1 | |a Selkoe, Dennis J |e verfasserin |4 aut | |
| 700 | 1 | |a Scannevin, Robert H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |d 2007 |g 19(2022), 3 vom: 31. Apr., Seite 1018-1036 |w (DE-627)NLM167471872 |x 1878-7479 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:3 |g day:31 |g month:04 |g pages:1018-1036 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13311-022-01199-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 3 |b 31 |c 04 |h 1018-1036 | ||